Overview
TRIANA Biomedicines is a greater Boston biotechnology company building the leading molecular glue discovery platform to regulate disease targets that are difficult to address with any other modality. TRIANA’s drug discovery engine is powered by high- resolution structural insights, state-of-the-art AI and computational tools, and bespoke chemical libraries. TRIANA’s target first and rational approach to molecular glue discovery is currently focused on inducing or enhancing the degradation of high-profile cancer targets. The therapeutic approach pioneered by TRIANA has the potential to fundamentally change the paradigm of small molecule drug discovery and bring significant therapeutic benefits to patients. TRIANA Biomedicines was seeded by RACapital Management and Atlas Venture.